- Home
- CTO vs ORIC Comparison
CTO vs ORIC Comparison
Compare CTO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- ORIC
- Stock Information
- Founded
- CTO 1902
- ORIC 2014
- Country
- CTO United States
- ORIC United States
- Employees
- CTO N/A
- ORIC N/A
- Industry
- CTO Real Estate Investment Trusts
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- ORIC Health Care
- Exchange
- CTO Nasdaq
- ORIC Nasdaq
- Market Cap
- CTO 568.5M
- ORIC 362.9M
- IPO Year
- CTO N/A
- ORIC 2020
- Fundamental
- Price
- CTO $17.33
- ORIC $11.20
- Analyst Decision
- CTO Strong Buy
- ORIC Strong Buy
- Analyst Count
- CTO 3
- ORIC 9
- Target Price
- CTO $22.33
- ORIC $18.29
- AVG Volume (30 Days)
- CTO 410.0K
- ORIC 887.8K
- Earning Date
- CTO 07-29-2025
- ORIC 08-11-2025
- Dividend Yield
- CTO 8.74%
- ORIC N/A
- EPS Growth
- CTO N/A
- ORIC N/A
- EPS
- CTO N/A
- ORIC N/A
- Revenue
- CTO $132,203,000.00
- ORIC N/A
- Revenue This Year
- CTO $20.11
- ORIC N/A
- Revenue Next Year
- CTO $8.51
- ORIC N/A
- P/E Ratio
- CTO N/A
- ORIC N/A
- Revenue Growth
- CTO 17.48
- ORIC N/A
- 52 Week Low
- CTO $16.12
- ORIC $3.90
- 52 Week High
- CTO $21.15
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- CTO 41.83
- ORIC 62.77
- Support Level
- CTO $17.26
- ORIC $10.60
- Resistance Level
- CTO $17.78
- ORIC $11.45
- Average True Range (ATR)
- CTO 0.35
- ORIC 0.56
- MACD
- CTO 0.01
- ORIC -0.08
- Stochastic Oscillator
- CTO 50.00
- ORIC 64.71
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.